Clinical Trials
91
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (83 trials with phase data)• Click on a phase to view related trials
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1
- Registration Number
- NCT02117050
- Locations
- 🇺🇸
Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 15
- Registration Number
- NCT02083679
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 253
- Registration Number
- NCT02070978
- Locations
- 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸University of Alabama at Birmingham - (UAB), Birmingham, Alabama, United States
🇺🇸Wallace Rheumatic Study Center, Beverly Hills, California, United States
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 35
- Registration Number
- NCT02049151
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 97
- Registration Number
- NCT02019550
- Locations
- 🇺🇸
Research site, Mansfield, Texas, United States
🇺🇸Research Site, Knoxville, Tennessee, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Dual Immunotherapy Combination Significantly Extends Survival in Advanced Cutaneous Squamous Cell Carcinoma
A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma.
Pimicotinib Achieves 54% Response Rate in Phase 3 Trial for Rare Joint Tumor
Pimicotinib demonstrated a statistically significant 54.0% objective response rate versus 3.2% for placebo in the global Phase 3 MANEUVER trial for tenosynovial giant cell tumor.
PhaseV Secures $50M Series A to Transform Clinical Trials with AI Platform
PhaseV has raised $50 million in Series A funding led by Accel and Insight Partners, bringing its total funding to $65 million to expand its AI-driven clinical development platform.
Walden Biosciences Strengthens Board with Appointment of Rare Disease Expert Howard Mayer
Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.
Bionxt Solutions to Evaluate Sublingual Cladribine Formulation for Multiple Sclerosis in Clinical Trial
Bionxt Solutions plans to initiate a clinical trial in the second half of 2025 to assess its sublingual cladribine formulation, BNT23001, for treating multiple sclerosis.
Patient-Centric Approaches and Technology Reshape Clinical Trial Landscape, Industry Experts Report
Only 39% of clinical trial sites achieve enrollment targets according to Tufts Center, highlighting critical recruitment challenges in drug development.